Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Lineage Therap ( (LCTX) ) is now available.
On November 12, 2025, Lineage Cell Therapeutics, Inc. sold 12,000,000 common shares to Janus Henderson Investors at $1.75 per share, generating $21 million in gross proceeds. This transaction, conducted under its at-the-market offering program, is expected to bolster the company’s financial position and support its ongoing operations and strategic initiatives.
The most recent analyst rating on (LCTX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.
Spark’s Take on LCTX Stock
According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.
Lineage Therap’s overall stock score is primarily influenced by its financial performance challenges, with ongoing losses and cash flow issues. Technical analysis shows positive momentum, providing some support. Valuation remains a concern due to negative earnings, while the earnings call highlights potential long-term growth through clinical advancements and partnerships.
To see Spark’s full report on LCTX stock, click here.
More about Lineage Therap
Lineage Cell Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cell therapies for degenerative diseases.
Average Trading Volume: 1,762,758
Technical Sentiment Signal: Buy
Current Market Cap: $416.9M
For an in-depth examination of LCTX stock, go to TipRanks’ Overview page.